COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS
Provided herein are methods of treating, preventing or managing atherosclerosis by administering a PDE4 modulator. Pharmaceutical compositions, dosage forms, and kits suitable for use in methods are also provided.
1 . An effective amount of a compound being a PDE4 modulator for use in a method for treating, preventing or managing atherosclerosis, wherein the method comprises administering the compound to a subject in need thereof.
2 . The compound for use of claim 1 , wherein the compound is:
or an enantiomer thereof, or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.
3 . The compound for use of claim 2 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof; or wherein the compound is
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof; or wherein the compound is
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.
4 . The compound for use of claim 1 , wherein the subject is suffering from rheumatoid arthritis, psoriasis, or psoriatic arthritis.
5 . An effective amount of a compound being a PDE4 modulator for use in a method for treating, preventing or managing atherosclerotic cardiovascular disease, wherein the method comprises administering the compound to a subject in need thereof.
6 . The compound for use of claim 5 , wherein the compound is:
or an enantiomer thereof, or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.
7 . The compound for use of claim 6 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof; or wherein the compound is
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof; or wherein the compound is
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.
8 . The compound for use of claim 5 , wherein the subject is suffering from rheumatoid arthritis, psoriasis, or psoriatic arthritis.
9 . The compound for use of claim 5 , wherein the subject is suffering from rheumatoid arthritis.
10 . The compound for use of claim 5 , wherein the subject is suffering from psoriasis.
11 . The compound for use of claim 5 , wherein the subject is suffering from psoriatic arthritis.
12 . An effective amount of a compound being a PDE4 modulator for use in a method for treating a symptom associated with atherosclerosis, wherein the method comprises administering the compound to a subject in need thereof.
13 . The compound for use of claim 12 , wherein the compound is:
or an enantiomer thereof, or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.
14 . The compound for use of claim 13 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof; or wherein the compound is
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof; or wherein the PDE4 modulator is
or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.
15 . The compound for use of claim 12 , wherein the subject is suffering from rheumatoid arthritis, psoriasis, or psoriatic arthritis.
16 . The compound for use of claim 12 , wherein the symptom is angina, shortness of breath, arrhythmia, a sleep problem, lack of energy, fatigue, sudden weakness, numbness, paralysis, trouble in seeing objects, dizziness, loss of consciousness, severe headache, or claudication.
17 . The compound for use of any one of claims 1 - 16 , wherein the method comprises oral administration of the compound.
18 . The compound for use of claim 17 , wherein the method comprises the administration of the compound in form of a tablet, capsule, or sachet.
19 . The compound for use of any one of claims 1 - 16 , wherein the method further comprises administering one or more additional active agents.